Abstract
Pancreatic adenocarcinoma (PAAD) is a deadly digestive system tumor with a poor prognosis. Recently, necroptosis has been considered as a type of inflammatory programmed cell death. However, the expression of necroptosis-related genes (NRGs) in PAAD and their associations with prognosis remain unclear. NRGs’ prediction potential in PAAD samples from The TCGA and GEO datasets was investigated. The prediction model was constructed using Lasso regression. Co-expression analysis showed that gene expression was closely related to necroptosis. NRGs were shown to be somewhat overexpressed in high-risk people even when no other clinical symptoms were present, indicating that they may be utilized in a model to predict PAAD prognosis. GSEA showed immunological and tumor-related pathways in the high-risk group. Based on the findings, immune function and m6A genes differ significantly between the low-risk and high-risk groups. MET, AM25C, MROH9, MYEOV, FAM111B, Y6D, and PPP2R3A might be related to the oncology process for PAAD patients. Moreover, CASKIN2, TLE2, USP20, SPRN, ARSG, MIR106B, and MIR98 might be associated with low-risk patients with PAAD. NRGs and the relationship of the immune function, immune checkpoints, and m6A gene expression with NRGs in PAAD may be considered as potential therapeutic targets that should be further studied.
Highlights
Pancreatic adenocarcinoma (PAAD) is considered as a fatal gastrointestinal tumor globally, with a death rate that is comparable to its incidence [1]
necroptosis‐related genes (NRGs) were shown to be somewhat overexpressed in high‐risk people even when no other clinical symptoms were present, indicating that they may be utilized in a model to predict PAAD prognosis
We found 25 difference of NRGs expression (DEGs) related to the Cancer Genome Atlas (TCGA) (7 upregulated, 18 downregulated; Figure 2A, Supplementary Table 2)
Summary
Pancreatic adenocarcinoma (PAAD) is considered as a fatal gastrointestinal tumor globally, with a death rate that is comparable to its incidence [1]. Surgical resection is the only drastic therapy, but the prognosis is dismal. Primary screening of high-risk factors of PAAD has no standard. CT, MRI, positron emission tomography/computed tomography is utilized to diagnose PAAD [2]. Most patients with PPAD are already in advanced stages, and they have missed the opportunity for surgical treatment after being diagnosed. The curative impact of radiation and chemotherapy for PAAD is not precise [3]. Considering that molecularly targeted therapy has become an indispensable method of treating malignant tumors, identifying novel therapeutic targets is critical
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
